– USA, MI – Esperion Therapeutics (NASDAQ: ESPR) today announced the appointment of Alan Fuhrman to its Board of Directors with a term expiring at the 2022 meeting of stockholders.
“On behalf of the Lipid Management team and our directors, I am very pleased to welcome Alan to the Esperion board. His extensive financial leadership experience will be extremely valuable as Esperion transitions to both developing and commercializing oral, LDL-C lowering medicines,” said Tim Mayleben, president and CEO.
“With the recent U.S. approvals of the NEXLETOLTM and NEXLIZETTM tablets, we are poised to deliver on the commercial promise of our medicines while continuing to advance the development of oral, once-daily LDL-C lowering medicines for the millions of patients in need. Alan’s accounting and financial acumen will help the company to successfully and responsibly navigate these opportunities for our shareholders,” he added.
About Alan Fuhrman
Mr. Fuhrman brings over 20 years of executive financial experience in biotechnology, medical devices, technology and services. He has experience in a wide variety of both public and private company financial transactions. Mr. Fuhrman is a member of the board of directors for SpringWorks Therapeutics and is a member of the board of directors of Checkmate Pharmaceuticals. Alan is currently CFO of Amplyx Pharmaceuticals, a biotechnology company focused on developing novel products for life-threatening infections. He previously served as CFO of Mirna Therapeutics, a clinical-stage microRNA company that merged with Synlogic in August 2017 and at Ambit Biosciences, where he helped lead the company through its initial public offering and oversaw financial, investor and administrative operations until its sale to Daiichi Sankyo in 2014.
“I’m pleased to be joining Esperion at this pivotal time in their evolution,” said Mr. Fuhrman. “I’m confident in the mission of the Esperion team to deliver lipid management for everybody. There are millions of patients that stand to benefit from the company’s ability to successfully execute on its commercial strategy.”
About Esperion Therapeutics
Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world.
For more information: https://www.esperion.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.